Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
He Sike,Liu Haoyang,Chen Junru,et al.Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy[J].Journal Of Translational Medicine.2024,22(1):232.doi:10.1186/s12967-024-05014-z.
APA：
He Sike,Liu Haoyang,Chen Junru&Zeng Hao.(2024).Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy.Journal Of Translational Medicine,22,(1)
MLA：
He Sike,et al."Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy".Journal Of Translational Medicine 22..1(2024):232
医学